Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XL309 (ISM3091) Monotherapy and Combination with Olaparib in Advanced Solid Tumors
NCT05932862Phase 1Recruiting
- Sponsor
- Exelixis, Inc.
- Start
- Apr 2024
- Primary completion
- Jan 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ISM0003091 in solid tumor (4 arms), sponsored by Exelixis, Inc. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 24 months, Incidence of Dose-Limiting Toxicities at 24 months and 6 more. Started Apr 2024; status: recruiting.
02
Drugs
ISM0003091
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05932862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05932862.